CervoMed Reports 2025 Results, Advances Neflamapimod Programs

CervoMed ( (CRVO) ) has shared an update.

On March 17, 2026, CervoMed reported fourth quarter and full-year 2025 results alongside updates on its neflamapimod pipeline, highlighting positive Phase 2b RewinD-LB data in dementia with Lewy bodies presented in 2025 and regulatory alignment with the FDA and other global agencies on a Phase 3 trial design. The company, which ended 2025 with $20.9 million in cash and a net loss of $27.0 million, plans to initiate a global Phase 3 DLB study and deliver multiple data readouts across stroke recovery, primary progressive aphasia and ALS in the second half of 2026, though these plans hinge on securing additional funding amid rising R&D and G&A expenses.

CervoMed also strengthened its position through issuance of new neflamapimod patents in Europe, Japan and China, the inclusion of the drug in the UK EXPERTS-ALS platform, and the hiring of a new chief commercial and business officer and a new board member in late 2025. Collectively, the clinical momentum, expanded intellectual property and upcoming catalysts underscore CervoMed’s bid to establish neflamapimod as a potential first-in-class therapy for multiple neurodegenerative indications, while its limited cash runway of roughly six months from the release date underscores financing risk for investors and partners.

The most recent analyst rating on (CRVO) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.

Spark’s Take on CRVO Stock

According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.

Score is held down primarily by weak financial performance (no revenue, worsening losses, and rising cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate updates provide some upside potential, but they do not yet offset near-term funding and momentum risks; valuation signals are limited due to negative earnings.

To see Spark’s full report on CRVO stock, click here.

More about CervoMed

CervoMed Inc. is a clinical-stage biotechnology company focused on developing neflamapimod, an orally administered small-molecule targeting age-related neurodegenerative brain disorders such as dementia with Lewy bodies, ischemic stroke recovery, primary progressive aphasia and amyotrophic lateral sclerosis. The company is listed on Nasdaq under the ticker CRVO and is expanding its global intellectual property portfolio and clinical collaborations to support late-stage development of neflamapimod.

Average Trading Volume: 88,198

Technical Sentiment Signal: Sell

Current Market Cap: $39.91M

See more insights into CRVO stock on TipRanks’ Stock Analysis page.